Mental disability often occurs after cardiac surgery, which may be due to inflammation of the brain. Prophylactic cortisone treatment may suppress the brain inflammation and reduce the degree of mental disability after cardiac surgery.

Prophylactic treatment with methylprednisolone may reduce the cerebral inflammatory response and reduce the severity of cognitive dysfunction after cardiac surgery

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2012-004232-37-SE

Enrollment

Registered

2012-10-02

Start date

2012-11-29

Completion date

Unknown

Last updated

2024-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Trade Name: Solu-Medrol Metylprednisolon Pharmaceutical Form: Solution for injection INN or Proposed INN: Metylprednisolon Other descriptive name: METHYLPREDNISOLONE SODIUM SUCCINATE Concentration uni

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 15 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 15

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Sweden

Contacts

Public ContactANOPIVA

Sahlgrenska Universitetssjukhuset

raija.saikkonen@vgregion.se46(0)31342 10 00 7798

Outcome results